CPA
TVTX icon

Capital Performance Advisors’s Travere Therapeutics TVTX Stock Holding History

Capital Performance Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-458
Closed -$6.41K – 2508
2024
Q3 		$6.41K Buy
+458
New +$4.77K ﹤0.01% 1009

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital Performance Advisors's TVTX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Travere Therapeutics (TVTX) in Q4 2024, closing a stake of 458 shares — an estimated $6.41K sold.

Capital Performance Advisors first reported a position in TVTX in Q3 2024 and held it in 1 quarter. The position peaked at $6.41K in Q3 2024. 197 funds tracked by Wall St. Rank hold TVTX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Travere Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 458 Travere Therapeutics shares in Q4 2024, an estimated $6.41K.
  • Capital Performance Advisors first reported a position in Travere Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Travere Therapeutics position peaked at $6.41K in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.